Pharmaceuticals, Biotechnology and Life Sciences
Oral presentation to include topline efficacy and safety data for 6 patients with up to 9 months of follow up Enrollment…
Adjustment of 2025 full-year financial targets Villepinte, 15 September 2025, 5.45 p.m.: Guerbet (FR0000032526 GBT), a global specialist in…
Leiden, The Netherlands – September 15, 2025 – ProteoNic, a leader in premium vector technology for biologics and cell and…
Texas hemp company recognized for exceptional quality, precision dosing, and pioneering consumer educationSAN ANTONIO, Sept. 15, 2025 (GLOBE NEWSWIRE) —…
New data show how Sympazan is being used in daily clinical practice to treat patients with Lennox-Gastaut Syndrome (LGS), a…
Preclinical Data for OPK-8801003 Demonstrate Substantially Longer Biological Half-Life with Peak Plasma Levels Comparable to Gattex®, the Only Approved GLP-2…
PRESS RELEASE – 09/15/2025, 09:00 AM EDT Biocartis Receives FDA Approval for the Idylla™ CDx MSI Test First-ever fully automated,…
Current XanaMIA pivotal phase 2/3 trial on track for interim analysis in January 2026 and final results late 2026 with…
Oral semaglutide (Rybelsus®) is now the first and only oral GLP-1 RA approved for type 2 diabetes, with proven cardiovascular…
Revised label allows treatment of DEB patients from birth VYJUVEK can now be applied by patients and caregivers PITTSBURGH, Sept.…